DHL Supply Chain Commits $400M Toward Pharma and Med Device Network Expansion
Logistics provider’s investment will develop distribution area by an additional 27%
DHL Supply Chain, a logistics company that operates within Deutsche Post DHL Group, announced that its life sciences and healthcare (LSHC) sector is investing upwards of $400 million to grow its pharma and medical device distribution network footprint by 27 percent this year, which totals nearly 3 million additional square feet. The company’s new investment features six new US sites by the end of 2022—making it a total of 34 by year’s end—and will include costs to invest in new buildings and technology, along with the fit-out and start-up of new or expanded operations.
The new facilities will be fully licensed with temperature-controlled space that supports pharma storage requirements, while also allowing for integrated solutions to accommodate both packaging and managed transportation.
“This latest investment in our life sciences and healthcare sector is testament to our track record and pedigree for delivering unrivalled supply chain expertise to our partners,” says Jim Saponaro, president, life sciences & healthcare, DHL Supply Chain North America. “This substantial expansion will only further deepen the connections between our customers and the patients they serve by providing best-in-class end-to-end supply chain solutions.”
